Gene Therapy Center at UC Davis Health in Sacramento. We currently have 59 clinical trials of gene and/or cell therapy at UCD & a GMP Facility. Keeping busy! 😊
Sacramento, CA
Joined October 2019
- Tweets2.4K
- Following2.2K
- Followers2K
- Likes5.1K
UCDavis_Gene_Therapy retweeted
Great way to start the final month of the year with the publication of this collaborative work on how dopamine regualtes L-type channels in #neurons.
science.org/doi/10.1126/scis…
And we got the cover!!! @ucdavis, @UCDavisHealth
UCDavis_Gene_Therapy retweeted
Congrats to Capricor, PI Dr. Craig McDonald of @ucdavishealth & the patients for these exciting results. Thank you to our @CIRMnews - funded Alpha Clinic for assisting with the trial logistics & product formulation and delivery.
capricor.com/investors/news-…
How a 'healthy exchange of ideas' kick-started FDA's gene therapy push
“They view it as getting at the root causes of diseases, as opposed to managing life-threatening or life-altering disorders that are also very expensive to the healthcare system”
fiercebiotech.com/biotech/ho…
UCDavis_Gene_Therapy retweeted
That @US_FDA is recognizing here the urgent need for regulatory strategies to evolve to match the pace of scientific advances in ways that streamline bringing the science safely to patients is incredibly important. I hope these new policies provide a foundation that will eventually allow certain kinds of genetic surgeries to become as routine as life-saving conventional surgeries, in which the process is robust and standardized enough to be rapidly adapted to each patient, without the need for a separate multi-year regulatory process for each surgery.
Personalized therapies hold tremendous promise but challenge traditional models of drug and biologic development. The @US_FDA outlines a path to market entry for products where a randomized trial is not feasible. Learn more: nej.md/4nUQdcl
ALT Sounding Board "Nearly 30 years after the sequencing of the human genome, bespoke therapies are close to reality. The FDA will work as a partner and guide in ushering these therapies to market, and our regulatory strategies will evolve to match the pace of scientific advances." "FDA’s New Plausible Mechanism Pathway Vinay" by Prasad, M.D., M.P.H., and Martin A. Makary, M.D., M.P.H.
UCDavis_Gene_Therapy retweeted
On #StemCellAwarenessDay, we reflect on CIRM’s mission since 2004: advancing stem cell & gene therapy research in California. To date, we've approved $4.6B to support innovation, education, & infrastructure. Take this fun quiz made by a CIRM Scholar: findyourstemcell.netlify.app…
ALT Graphic of text that says 'What kind of stem cell are you? The Originator (totipotent stem cell), The Lifeline (hematopoietic stem cell), The Reprogrammer (induced pluripotent stem cell), The Healer (mesenchymal stem cell), The Thinker (neural stem cell), andThe Shape-Shifter (embryonic stem cell)'.
UCDavis_Gene_Therapy retweeted
Congratulations to @uniQure_NV and to the #huntingtonsdisease community! 💙💜
uniqure.com/investors-media/…
UCDavis_Gene_Therapy retweeted
Advancing Gene Editing Therapeutics: Clinical Trials and Innovative Delivery Systems across Diverse Diseases dlvr.it/TMJTBd #MTNA
UCDavis_Gene_Therapy retweeted
Since 2006, CIRM has committed $447M to fund training for 4,600+ #biomedical students in regenerative medicine. These programs help prepare the workforce that will turn today’s scientific discoveries into tomorrow’s treatments.
blog.cirm.ca.gov/2025/07/21/…
UCDavis_Gene_Therapy retweeted
This study makes a contribution to the understanding of the pathophysiology of Huntington's disease. The results reveal the disruptive impact of mHTT on the development of medium spiny neurons that likely contributes to neurodegeneration.
doi.org/10.1093/stmcls/sxaf0…
UCDavis_Gene_Therapy retweeted
A systemically deliverable lipid-conjugated siRNA targeting DUX4 as an Facioscapulohumeral Muscular Dystrophy therapeutic dlvr.it/TLKfv0 #MTMCD
There is at least some hope for those of us in the cell and gene therapy field. 🧬Hopefully this enthusiasm translates into more @NIH funding for scientists in the USA. 🙏 Without funding there are no cures.
To our colleagues and students in #Celltherapy and #Genetherapy, I know MANY of you have submitted applications to move outside of the USA due to the major cuts to @NIH funding, and it has seemed hopeless to stay here, due to the "war on science". Please watch this video, give them a chance, and STAY! We can't afford to lose our most brilliant scientists and students, we can't save lives without you. 🙏
Our patients, especially those with #rarediseases, need you.
UCDavis_Gene_Therapy retweeted
Targeting DNA damage in ageing: towards supercharging DNA repair nature.com/articles/s41573-0…
This new Review discusses approaches to pharmacologically mitigate the adverse effects of DNA damage to prevent mutation-driven cancers and mitigate age-related degenerative diseases
Our CA CAR-T 299 clinical trial has outcome results comparable to commercial products for relapsed DLBCL. We manufacture the T Cell product for $50k and deliver fresh cells, one week vein-to- vein.
#pointofcare #GMP #academicGMP
UCDavis_Gene_Therapy retweeted
Thanks for highlighting the review from Dr Levine et al on CAR T published in @cytotherapy
Take a look at the next innovations in CAR T cell immunotherapies for cancer!
Enjoy reading this review by Dr. Levine (@BLLPHD) and colleagues. 👇
UCDavis_Gene_Therapy retweeted
The @US_FDA will be hosting a roundtable on cell and gene therapy, livestreaming TODAY, at 2pm-5pm BST / 9am-12pm ET, on YouTube and X. Some panelists include:
Nicole Verdun (FDA), Carl June (University of Pennsylvania), Tim Hunt (Alliance for Regenerative Medicine), Catherine Bollard (Stanford University), David Lui (Harvard University), Jeff Allen (Friends of Cancer Research) and Ron Bartek (Friedreich's Ataxia Research Alliance). To view the rest of the panelists, click here >>> hubs.ly/Q03qR1310
To watch the livestream on YouTube, click here >>> hubs.ly/Q03qR10c0
To watch the livestream on X, click here >>> hubs.ly/Q03qQSbb0
UCDavis_Gene_Therapy retweeted
For readers interested in CRISPR-based therapies, this recent review covers chemical engineering of CRISPR–Cas systems for therapeutic applications
nature.com/articles/s41573-0…
rdcu.be/epryC
UCDavis_Gene_Therapy retweeted
Baby KJ, the world's first patient to receive personalized CRISPR gene editing therapy for a rare metabolic disease, is now home and thriving! This groundbreaking treatment offers hope for other untreatable genetic conditions. #CRISPR #GeneEditing yahoo.com/news/worlds-first-…
UCDavis_Gene_Therapy retweeted
No words - only tears of joy. And bow of gratitude to Rebecca Ahrens-nicklas (CHOP) and Kiran Musunuru (Penn) and Sadik Kassim (Danaher) - our amazing partners in designing, derisking, and administering a CRISPR on demand to Baby KJ.
In case you needed a smile this Tuesday: 10-month-old baby KJ, who received a bespoke gene-editing therapy after a six month scientific sprint - "graduated" from the hospital today and went HOME! YAY SCIENCE! Here's his story: wapo.st/451ZQjT
UCDavis_Gene_Therapy retweeted
A few weeks ago we introduced you to KJ, who made medical history as the first patient to receive a personalized gene editing therapy. After almost a year at CHOP, KJ is now at home with his family. 🎓
Tune in to NBC's @TODAYshow tomorrow morning to hear from his family!
UCDavis_Gene_Therapy retweeted
Biotech Webinar – June 6 @ 3PM ET
T Cell Selection: A Critical Step in the CAR-T Process
How do we isolate T cells—and why does it matter for access?
🔗 Register: caringcross.org/events/
#CART #CellTherapy #Biotech #HealthEquity
